304 related articles for article (PubMed ID: 27655711)
21. Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
Sameni M; Tovar EA; Essenburg CJ; Chalasani A; Linklater ES; Borgman A; Cherba DM; Anbalagan A; Winn ME; Graveel CR; Sloane BF
Clin Cancer Res; 2016 Feb; 22(4):923-34. PubMed ID: 26432786
[TBL] [Abstract][Full Text] [Related]
22. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
23. Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.
Bao B; Mitrea C; Wijesinghe P; Marchetti L; Girsch E; Farr RL; Boerner JL; Mohammad R; Dyson G; Terlecky SR; Bollig-Fischer A
Sci Rep; 2017 Mar; 7():44125. PubMed ID: 28281569
[TBL] [Abstract][Full Text] [Related]
24. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
Gaule PB; Crown J; O'Donovan N; Duffy MJ
Expert Opin Ther Targets; 2014 Sep; 18(9):999-1009. PubMed ID: 25084805
[TBL] [Abstract][Full Text] [Related]
25. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
[TBL] [Abstract][Full Text] [Related]
26. Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A.
Breen L; Gaule PB; Canonici A; Walsh N; Collins DM; Cremona M; Hennessy BT; Duffy MJ; Crown J; Donovan NO; Eustace AJ
Invest New Drugs; 2020 Oct; 38(5):1365-1372. PubMed ID: 32318883
[TBL] [Abstract][Full Text] [Related]
27. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
Nakai K; Xia W; Liao HW; Saito M; Hung MC; Yamaguchi H
Breast Cancer; 2018 Jan; 25(1):74-80. PubMed ID: 28643125
[TBL] [Abstract][Full Text] [Related]
28. MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.
Yip C; Foidart P; Somja J; Truong A; Lienard M; Feyereisen E; Schroeder H; Gofflot S; Donneau AF; Collignon J; Delvenne P; Sounni NE; Jerusalem G; Noël A
Br J Cancer; 2017 Mar; 116(6):742-751. PubMed ID: 28196064
[TBL] [Abstract][Full Text] [Related]
29. Novel strategy for a bispecific antibody: induction of dual target internalization and degradation.
Lee JM; Lee SH; Hwang JW; Oh SJ; Kim B; Jung S; Shim SH; Lin PW; Lee SB; Cho MY; Koh YJ; Kim SY; Ahn S; Lee J; Kim KM; Cheong KH; Choi J; Kim KA
Oncogene; 2016 Aug; 35(34):4437-46. PubMed ID: 26853467
[TBL] [Abstract][Full Text] [Related]
30. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
31. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
Montero JC; Esparís-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocaña A; Pandiella A
Oncogene; 2014 Jan; 33(2):148-56. PubMed ID: 23246963
[TBL] [Abstract][Full Text] [Related]
32. Near-infrared photothermal therapy using EGFR-targeted gold nanoparticles increases autophagic cell death in breast cancer.
Zhang M; Kim HS; Jin T; Moon WK
J Photochem Photobiol B; 2017 May; 170():58-64. PubMed ID: 28390259
[TBL] [Abstract][Full Text] [Related]
33. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
34. PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway.
Ma Y; Fang Z; Zhang H; Qi Y; Mao Y; Zheng J
Cell Death Dis; 2024 Apr; 15(3):199. PubMed ID: 38604999
[TBL] [Abstract][Full Text] [Related]
35. Crizotinib and erlotinib inhibits growth of c-Met
Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
[TBL] [Abstract][Full Text] [Related]
36. [MET receptor inhibition: Hope against resistance to targeted therapies?].
Hochart A; Leblond P; Le Bourhis X; Meignan S; Tulasne D
Bull Cancer; 2017 Feb; 104(2):157-166. PubMed ID: 27863726
[TBL] [Abstract][Full Text] [Related]
37. Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer.
Jaradat SK; Ayoub NM; Al Sharie AH; Aldaod JM
Technol Cancer Res Treat; 2024; 23():15330338241234780. PubMed ID: 38389413
[TBL] [Abstract][Full Text] [Related]
38. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
[TBL] [Abstract][Full Text] [Related]
39. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
40. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
